Axogen Inc vs Nvidia Corp — how do they compare? Axogen Inc trades at $48.35 (market cap $2.61B), while Nvidia Corp trades at $220.01 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 2019.2× Axogen Inc's market cap, and Nvidia Corp pays a 0.46% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | NVDA | |
|---|---|---|
Market Cap | $2.61B | $5.27T |
Sector | Technology | Technology |
52-Week High | $48.48 | $235.75 |
52-Week Low | $14.16 | $165.17 |
Enterprise Value | $2.52B | $5.20T |
Dividend Yield | — | 0.46% |
Signals from Pluang's Aura AI — not financial advice
AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.
The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.
NVIDIA (NVDA) trades at $217.56, down 2.86% on the day, amid a broader tech sell-off. The stock maintains a bullish technical outlook with strong moving averages, though the 6-day RSI suggests overbought conditions near-term. Fundamentally, the company reported record revenue of $130.5B in 2025 with a net income margin of 62.97%, driven by AI chip demand. Recent earnings have consistently beaten estimates, and the company announced a $0.25 dividend payable in June 2026.
Outlook remains positive given NVIDIA's dominance in AI infrastructure, with a consensus price target of $325.86 implying significant upside. Risks include heightened valuations, competitive pressures, and macroeconomic sensitivity. Investor sentiment is buoyed by analyst optimism, with 75% recommending Buy, but news highlights concerns over growth sustainability as the company scales.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →